Research classified by Journal of Economic Literature (JEL) codes

2018

• Mariana Carrera & Dana P. Goldman & Geoffrey Joyce & Neeraj Sood, 2018, "Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?," American Economic Journal: Economic Policy, American Economic Association, volume 10, issue 1, pages 113-152, February.
• Liran Einav & Amy Finkelstein & Maria Polyakova, 2018, "Private Provision of Social Insurance: Drug-Specific Price Elasticities and Cost Sharing in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, volume 10, issue 3, pages 122-153, August.
• Kurt Lavetti & Kosali Simon, 2018, "Strategic Formulary Design in Medicare Part D Plans," American Economic Journal: Economic Policy, American Economic Association, volume 10, issue 3, pages 154-192, August.
• Darius N. Lakdawalla, 2018, "Economics of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, volume 56, issue 2, pages 397-449, June.
• Maria-Silvia Sandulescu & Drago? Andrei Stoica & Catalin-Nicolae Albu & Nadia Albu, 2018, "Types of Intellectual Capital Employed in Bioeconomic Projects – A Longitudinal Case Study," The AMFITEATRU ECONOMIC journal, Academy of Economic Studies - Bucharest, Romania, volume 20, issue 49, pages 667-667, August.
• Kseniya Yurtayeva & Yevhenia Hladkova & Alona Shcherbakova, 2018, "Role Of Mass Media In Combating Drug-Related Crime," Baltic Journal of Economic Studies, Publishing house "Baltija Publishing", volume 4, issue 3, DOI: 10.30525/2256-0742/2018-4-3-366-371.
• Plamena Nedyalkova, 2018, "Features, Characteristics and Methodology of Internal Control over Nanotech Manufacturing and Nano-Production in Food Industry," Economic Studies journal, Bulgarian Academy of Sciences - Economic Research Institute, issue 3, pages 157-189.
• Melissa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018, "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers, Barcelona School of Economics, number 1042, Jun.
• Marco Ceccagnoli & Matthew J. Higgins & Hyunsung D. Kang, 2018, "Corporate venture capital as a real option in the markets for technology," Strategic Management Journal, Wiley Blackwell, volume 39, issue 13, pages 3355-3381, December, DOI: 10.1002/smj.2950.
• Kang Hyunsung D, 2018, "A Start-Up’s R&D Stages and the Evolution of Financing Sources: Evidence from the Biotechnology Industry," Entrepreneurship Research Journal, De Gruyter, volume 8, issue 3, pages 1-19, July, DOI: 10.1515/erj-2017-0159.
• Lichtenberg Frank R., 2018, "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis," Forum for Health Economics & Policy, De Gruyter, volume 21, issue 2, pages 1-20, December, DOI: 10.1515/fhep-2018-0009.
• Víctor Manuel NIETO & Santiago Alberto PEREA, 2018, "Cadena Productiva de Pinturas, Masillas, Pigmentos, Tintas y Removedores Estructura, Comercio Internacional y Protección," Archivos de Economía, Departamento Nacional de Planeación, number 16498, Aug.
• Carmen Padilla-Lozano & Danny Ar�valo-Avecillas & Nancy Wong-Laborde, 2018, "Influencia de la responsabilidad social en el desempeno financiero del sector químico-farmacéutico," Revista Equidad y Desarrollo, Universidad de la Salle, issue 32, pages 121-141, DOI: 10.19052/ed.4366.
• Kremer, Michael & Snyder, Christopher, 2018, "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global D," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 12751, Feb.
• Frank R. LICHTENBERG, 2018, "The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," JODE - Journal of Demographic Economics, Cambridge University Press, volume 84, issue 3, pages 309-354, September, DOI: 10.1017/dem.2018.11.
• Newham, M. & Seldeslachts, J. & Banal-Estanol, A., 2018, "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers, Department of Economics, City St George's, University of London, number 18/03.
• Lichtenberg, Frank R., 2018, "The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries," Journal of Demographic Economics, Cambridge University Press, volume 84, issue 3, pages 309-354, September.
• Debashis CHAKRABORTY & Sourabh MAHESHWARI & Sushil PARASHAR, 2018, "Recent US-China tariff war: Opportunities for Indian pharmaceutical exports?," Journal of Economics Bibliography, EconSciences Journals, volume 5, issue 4, pages 209-222, December.
• Atal, Juan Pablo & Cuesta, Jose Ignacio & Sæthre, Morten, 2018, "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Research Department working papers, CAF Development Bank Of Latinamerica, number 1211.
• Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018, "Common Ownership and Market Entry: Evidence from Pharmaceutical Industry," Discussion Papers of DIW Berlin, DIW Berlin, German Institute for Economic Research, number 1738.
• Granlund, David & Bergman, Mats A., 2018, "Price competition in pharmaceuticals – Evidence from 1303 Swedish markets," Journal of Health Economics, Elsevier, volume 61, issue C, pages 1-12, DOI: 10.1016/j.jhealeco.2018.06.009.
• Honjo, Yuji & Nagaoka, Sadao, 2018, "Initial public offering and financing of biotechnology start-ups: Evidence from Japan," Research Policy, Elsevier, volume 47, issue 1, pages 180-193, DOI: 10.1016/j.respol.2017.10.009.
• Lawrence Kryzanowski & Trang Phuong Tran, 2018, "Informed trading around biotech M&As," Studies in Economics and Finance, Emerald Group Publishing Limited, volume 35, issue 1, pages 44-64, March, DOI: 10.1108/SEF-10-2016-0257.
• Frank R. Lichtenberg, 2018, "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers, eSocialSciences, number id:12757, May.
• Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018, "Common ownership and market entry: Evidence from the pharmaceutical industry," Working Papers of Department of Management, Strategy and Innovation, Leuven, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven, number 623896, May.
• Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018, "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Discussion Paper Series in Economics, Norwegian School of Economics, Department of Economics, number 20/2018, Sep.
• Granlund, David & Rudholm, Niklas, 2018, "Risker och kostnader för prissamordningar på den svenska generikamarknaden," Umeå Economic Studies, Umeå University, Department of Economics, number 958, Jul.
• Luca Verginer & Massimo Riccaboni, 2018, "Brain-Circulation Network: The Global Mobility of the Life Scientists," Working Papers, IMT School for Advanced Studies Lucca, number 10/2018, Oct, revised Oct 2018.
• Michael Kremer & Christopher M. Snyder, 2018, "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, volume 53, issue 1, pages 235-273, August, DOI: 10.1007/s11151-018-9621-4.
• Christopher M. Snyder & Victor J. Tremblay, 2018, "Introduction to the Special Issue on “The Intersection Between Industrial Organization and Healthcare Economics”," Review of Industrial Organization, Springer;The Industrial Organization Society, volume 53, issue 1, pages 1-6, August, DOI: 10.1007/s11151-018-9628-x.
• John Hagedoorn & Boris Lokshin & Stéphane Malo, 2018, "Alliances and the innovation performance of corporate and public research spin-off firms," Small Business Economics, Springer, volume 50, issue 4, pages 763-781, April, DOI: 10.1007/s11187-017-9894-2.
• Martin Backfisch, 2018, "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung), number 201813.
• Ana Aizcorbe & Colin Baker & Ernst R. Berndt & David M. Cutler, 2018, "Measuring and Modeling Health Care Costs," NBER Books, National Bureau of Economic Research, Inc, number aizc13-1, January.
• Ernst R. Berndt & Mark R. Trusheim, 2018, "The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory," NBER Chapters, National Bureau of Economic Research, Inc, "Economic Dimensions of Personalized and Precision Medicine".
• Manuel Hermosilla & Jorge Lemus, 2018, "Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS," NBER Chapters, National Bureau of Economic Research, Inc, "Economic Dimensions of Personalized and Precision Medicine".
• Michael Kremer & Christopher M. Snyder, 2018, "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals," NBER Working Papers, National Bureau of Economic Research, Inc, number 24206, Jan.
• Barry Bosworth & John Bieler & Michael Kleinrock & Eric Koepcke & Ernst R. Berndt, 2018, "An Evaluation of the CPI Indexes for Prescription Drugs," NBER Working Papers, National Bureau of Economic Research, Inc, number 24210, Jan.
• Frank R. Lichtenberg, 2018, "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," NBER Working Papers, National Bureau of Economic Research, Inc, number 24536, Apr.
• Wallace P. Mullin & Christopher M. Snyder, 2018, "Revealed Growth: A Method for Bounding the Elasticity of Demand with an Application to Assessing the Antitrust Remedy in the Du Pont Decision," NBER Working Papers, National Bureau of Economic Research, Inc, number 24786, Jun.
• Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018, "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers, National Bureau of Economic Research, Inc, number 24957, Aug.
• Yujin Kim & Chirantan Chatterjee & Matthew J. Higgins, 2018, "Moving Beyond the Valley of Death: Regulation and Venture Capital Investments in Early-Stage Biopharmaceutical Firms," NBER Working Papers, National Bureau of Economic Research, Inc, number 25202, Oct.
• April Bhattacharjee & Mihir Dash, 2018, "Determinants of Capital Structure in the Indian Pharma Sector," Journal of Applied Management and Investments, Department of Business Administration and Corporate Security, International Humanitarian University, volume 7, issue 3, pages 125-131, September.
• Christos Kolympiris & Sebastian Hoenen & Nicholas Kalaitzandonakes, 2018, "Geographic distance between venture capitalists and target firms and the value of quality signals," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 27, issue 1, pages 189-220.
• Eric Brouillat & Maïder Saint Jean & Nabila Arfaoui, 2018, "“Reach for the sky”: modeling the impact of policy stringency on industrial dynamics in the case of the REACH regulation," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 27, issue 2, pages 289-320.
• Osamu Suzuki, 2018, "Enabling or constraining? Unraveling the influence of organizational slack on innovation," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 27, issue 3, pages 555-575.
• Francesca Di Iorio & Maria Letizia Giorgetti, 2018, "The impact of submarket concentration in the US pharmaceutical industry in 1987-1998," DEM Working Papers Series, University of Pavia, Department of Economics and Management, number 163, Jun.
• Peilei Fan, 2018, "Catching Up in Economic Transition: Innovation in the People’s Republic of China and India," ADBI Working Papers, Asian Development Bank Institute, number 809, Feb.
• Daejong Gwak, 2018, "The Post-2020 Climate Regime and the Korean Cement Industry: Greenhouse Gases, Energy Efficiency and Policy Implications," Industrial Economic Review, Korea Institute for Industrial Economics and Trade, number 18-6, Apr.
• Béfort, Nicolas, 2018, "Régulation, verrous technologiques et transition écologique : le cas des formaldéhydes," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, volume 22.
• Varun Mahajan & D. K. Nauriyal & S. P. Singh, 2018, "Efficiency and Its Determinants: Panel Data Evidence from the Indian Pharmaceutical Industry," Margin: The Journal of Applied Economic Research, National Council of Applied Economic Research, volume 12, issue 1, pages 19-40, February, DOI: 10.1177/0973801017738416.
• Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2019, "The Economics Behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," CSEF Working Papers, Centre for Studies in Economics and Finance (CSEF), University of Naples, Italy, number 525, Mar, revised 13 May 2019.
• Bonwook Koo & Jiyoon Do & Jeasung Park & ByungJo Yu & In Park, 2018, "Derivatization of Commercial Vitamin A to Develop the Bio-based Anti-aging cosmetic materials," Proceedings of International Academic Conferences, International Institute of Social and Economic Sciences, number 7709559, Jul.
• Tien Lo & Ha Soo Hwang & In Park, 2018, "Fluoroalkyl-Modified Polysilazanes for Omniphobic Coatings," Proceedings of International Academic Conferences, International Institute of Social and Economic Sciences, number 7709584, Jul.
• Badi H. Baltagi & Peter H. Egger & Michaela Kesina, 2018, "Generalized spatial autocorrelation in a panel-probit model with an application to exporting in China," Empirical Economics, Springer, volume 55, issue 1, pages 193-211, August, DOI: 10.1007/s00181-017-1409-0.
• Melisa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018, "Common ownership and market entry: Evidence from the pharmaceutical industry," Economics Working Papers, Department of Economics and Business, Universitat Pompeu Fabra, number 1612, May.
• Witkowska Janina, 2018, "Corporate Social Responsibility (CSR) of Innovative Pharmaceutical Corporations. The Case of BIOGEN," Comparative Economic Research, Sciendo, volume 21, issue 3, pages 45-62, September, DOI: 10.2478/cer-2018-0018.
• ten Brink, Patrick & Schweitzer, Jean-Pierre & Watkins, Emma & Janssens, Charlotte & De Smet, Michiel & Leslie, Heather & Galgani, François, 2018, "Circular economy measures to keep plastics and their value in the economy, avoid waste and reduce marine litter," Economics Discussion Papers, Kiel Institute for the World Economy, number 2018-3.
• Kirchhoff, Jasmina, 2018, "Turbulentes Jahr 2017, gedämpfte Aussichten für 2018: Deutschlands Pharmaindustrie 2017/2018," IW-Reports, Institut der deutschen Wirtschaft (IW) / German Economic Institute, number 42/2018.
• Diel, Anastasia & Kirchhoff, Jasmina, 2018, "Gibt es einen Fachkräfteengpass in der deutschen Pharmaindustrie?
  [Is there a shortage of skilled workers in the german pharmaceutical industry?]," IW-Trends – Vierteljahresschrift zur empirischen Wirtschaftsforschung, Institut der deutschen Wirtschaft (IW) / German Economic Institute, volume 45, issue 3, pages 79-95, DOI: 10.2373/1864-810X.18-03-06.

2017

• Banu Yeşim Buyukakinci & Nihal Sokmen, 2017, "Investigation Of Indigo Dyeing Using Sodium Borohydride As Reducing Agent," CBU International Conference Proceedings, ISE Research Institute, volume 5, issue 0, pages 1061-1063, September, DOI: 10.12955/cbup.v5.1071.
• Manolis Galenianos & Alessandro Gavazza, 2017, "A Structural Model of the Retail Market for Illicit Drugs," American Economic Review, American Economic Association, volume 107, issue 3, pages 858-896, March.
• Anne Fitzpatrick, 2017, "Shopping While Female: Who Pays Higher Prices and Why?," American Economic Review, American Economic Association, volume 107, issue 5, pages 146-149, May.
• Adam Sacarny & David Yokum & Shantanu Agrawal, 2017, "Government-Academic Partnerships in Randomized Evaluations: The Case of Inappropriate Prescribing," American Economic Review, American Economic Association, volume 107, issue 5, pages 466-470, May.
• Margaret Kyle & Heidi Williams, 2017, "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," American Economic Review, American Economic Association, volume 107, issue 5, pages 486-490, May.
• Eric W. Bond & Kamal Saggi, 2017, "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," American Economic Journal: Microeconomics, American Economic Association, volume 9, issue 1, pages 31-62, February.
• Oleg Baranov & Christina Aperjis & Lawrence M. Ausubel & Thayer Morrill, 2017, "Efficient Procurement Auctions with Increasing Returns," American Economic Journal: Microeconomics, American Economic Association, volume 9, issue 3, pages 1-27, August.
• Colleen Carey, 2017, "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, volume 9, issue 1, pages 38-73, February.
• Ali Yurukoglu & Eli Liebman & David B. Ridley, 2017, "The Role of Government Reimbursement in Drug Shortages," American Economic Journal: Economic Policy, American Economic Association, volume 9, issue 2, pages 348-382, May.
• Leemore Dafny & Christopher Ody & Matt Schmitt, 2017, "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization," American Economic Journal: Economic Policy, American Economic Association, volume 9, issue 2, pages 91-123, May.
• Cezar, R., 2017, "L’industrie pharmaceutique française dans les chaînes de valeur mondiales," Bulletin de la Banque de France, Banque de France, issue 209, pages 57-69.
• Víctor Manuel NIETO & Gina Marcela CALDER�N, 2017, "Cadena de Productos Lácteos Estructura, Comercio Internacional y Protección," Archivos de Economía, Departamento Nacional de Planeación, number 15502, Apr.
• José Morelos Gómez & Miguel �ngel Nu?nez Bottini, 2017, "Productividad de las empresas de la zona extractiva minera-energética y su incidencia en el desempeno financiero en Colombia," Estudios Gerenciales, Universidad Icesi, volume 33, issue 145, pages 330-340.
• Jo Seldeslachts & Melissa Newham & Albert Banal-Estanol, 2017, "Changes in Common Ownership of German Companies," DIW Economic Bulletin, DIW Berlin, German Institute for Economic Research, volume 7, issue 30, pages 303-311.
• Jo Seldeslachts & Melissa Newham & Albert Banal-Estanol, 2017, "Veränderungen bei gemeinsamen Eigentümerstrukturen deutscher Unternehmen," DIW Wochenbericht, DIW Berlin, German Institute for Economic Research, volume 84, issue 30, pages 611-621.
• Baltagi, Badi H. & Egger, Peter H. & Kesina, Michaela, 2017, "Determinants of firm-level domestic sales and exports with spillovers: Evidence from China," Journal of Econometrics, Elsevier, volume 199, issue 2, pages 184-201, DOI: 10.1016/j.jeconom.2017.05.009.
• Banerjee, Tannista & Siebert, Ralph, 2017, "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, volume 46, issue 7, pages 1255-1271, DOI: 10.1016/j.respol.2017.05.009.
• Eric Brouillat & Maïder Saint Jean & Nabila Arfaoui, 2017, "“Reach for the sky”: modeling the impact of policy stringency on industrial dynamics in the case of the REACH regulation," Post-Print, HAL, number hal-02502669, Dec, DOI: 10.1093/icc/dtx029.
• Izabela Jelovac & Nicolas Houy, 2017, "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print, HAL, number halshs-01657274, Jun.
• Granlund, David & Bergman, Mats A., 2017, "Price competition in pharmaceuticals – evidence from 1303 Swedish markets," Umeå Economic Studies, Umeå University, Department of Economics, number 952, Aug.
• Natalia Shmatko & Alina Lavrynenko & Dirk Meissner, 2017, "Communicating Company Innovation Culture: Assessment Through Job Advertisements Analysis," HSE Working papers, National Research University Higher School of Economics, number WP BRP 74/STI/2017.
• John Romley & Tiffany Shih, 2017, "Product safety spillovers and market viability for biologic drugs," International Journal of Health Economics and Management, Springer, volume 17, issue 2, pages 135-158, June, DOI: 10.1007/s10754-016-9208-2.
• Philip E. Auerswald & Lokesh Dani, 2017, "The adaptive life cycle of entrepreneurial ecosystems: the biotechnology cluster," Small Business Economics, Springer, volume 49, issue 1, pages 97-117, June, DOI: 10.1007/s11187-017-9869-3.
• Chia-Lin Chang & Renu Sukharomana, 2017, "Demand for Narcotics in Thailand, with Policy Implications," Journal of Reviews on Global Economics, Lifescience Global, volume 6, pages 279-284.
• Martin Backfisch, 2017, "Have Pharmaceutical R&D Project Success Rates Decreased? A Critical Review and New Empirical Results," MAGKS Papers on Economics, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung), number 201746.
• Badi H. Baltagi & Peter H. Egger & Michaela Kesina, 2017, "Determinants of Firm-Level Domestic Sales and Exports with Spillovers: Evidence from China," Center for Policy Research Working Papers, Center for Policy Research, Maxwell School, Syracuse University, number 209, Sep.
• Francesca DI IORIO & Maria Letizia GIORGETTI, 2017, "A Deeper Analysis on Pharmaceutical Submarket Concentration: the US market in 1987-1998," Departmental Working Papers, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano, number 2017-02, Jan.
• Francesca DI IORIO & Maria Letizia GIORGETTI, 2017, "Entry and Patents: Evidence from the US Cardiovascular Pharmaceutical Sector," Departmental Working Papers, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano, number 2017-07, Apr.
• Ezio Ritrovato, 2017, "Energy Self-Sufficiency and the State Oil Industry. The Birth of ANIC," Rivista di storia economica, Società editrice il Mulino, issue 3, pages 351-387.
• Philippe Gorry & Diego Useche, 2018, "Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies," NBER Chapters, National Bureau of Economic Research, Inc, "Economic Dimensions of Personalized and Precision Medicine".
• Adam Jørring & Andrew W. Lo & Tomas J. Philipson & Manita Singh & Richard T. Thakor, 2017, "Sharing R&D Risk in Healthcare via FDA Hedges," NBER Working Papers, National Bureau of Economic Research, Inc, number 23344, Apr.
• Manuel I. Hermosilla & Jorge A. Lemus, 2017, "Therapeutic Translation of Genomic Science: Opportunities and limitations of GWAS," NBER Working Papers, National Bureau of Economic Research, Inc, number 23989, Nov.
• Ernst R. Berndt & Mark R. Trusheim, 2017, "The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory," NBER Working Papers, National Bureau of Economic Research, Inc, number 24020, Nov.
• Philippe Gorry & Diego Useche, 2017, "Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies," NBER Working Papers, National Bureau of Economic Research, Inc, number 24021, Nov.
• Yulia Nedelcheva, 2017, "External Factors For Outsourcing In Pharmaceutical Sector: Evidence From Bulgaria," Entrepreneurship, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, volume 5, issue 2, pages 106-123.
• Carolin Haeussler & Bastian Rake, 2017, "The changing geography of clinical research: a critical analysis of its drivers," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 26, issue 2, pages 285-310.
• Karen Ruckman & Ian McCarthy, 2017, "Why do some patents get licensed while others do not?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 26, issue 4, pages 667-688.
• Hakan Ener, 2017, "The unfulfilled promise of biotechnology firms: a top management team-based explanation," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 26, issue 5, pages 887-906.
• Sukharomana, Renu & Chang, Chia-Lin, 2017, "Demand for Narcotics in Thailand, with Policy Implications," MPRA Paper, University Library of Munich, Germany, number 79081, May.
• Mitze, Timo & Strotebeck, Falk, 2017, "Modeling interregional research collaborations in German biotechnology using industry directory data: A quantitative social network analysis," MPRA Paper, University Library of Munich, Germany, number 83392, Feb.
• Hajibabaei, Ehsan & Ghasmi, Alireza & Hosseini, Seyed Abbas, 2017, "Numerical Investigation of Head Frontal Velocity of nonconservative Dense Flows in Small Inclined Beds," MPRA Paper, University Library of Munich, Germany, number 88383, Feb, revised Jan 2017.
• Morales, Rosa & Radoniqi, Fatos, 2017, "Intangibles and the Market Value of Biopharmaceutical Startups," MPRA Paper, University Library of Munich, Germany, number 88580.
• Marlon Rojas & Leslie Arcila & Antonieta Rios & Abdu Orduña & Valentin Lopez & Orlando Zaca & Gerardo Muñoz, 2017, "Gold nanoparticles on the development of fluorescent biosensors for the detection of pathogenic bacteria in water and foods," Proceedings of International Academic Conferences, International Institute of Social and Economic Sciences, number 5907865, Oct.
• Thomas Brenner & Johann Peter Murmann, 2017, "Using Simulation Experiments to Test Historical Explanations: The Development of the German Dye Industry 1857–1913," Economic Complexity and Evolution, Springer, in: Andreas Pyka & Uwe Cantner, "Foundations of Economic Change", DOI: 10.1007/978-3-319-62009-1_18.
• Fernando Gascón & Jesús Lozano & Borja Ponte & David Fuente, 2017, "Measuring the efficiency of large pharmaceutical companies: an industry analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 18, issue 5, pages 587-608, June, DOI: 10.1007/s10198-016-0812-3.
• Bastian Rake, 2017, "Determinants of pharmaceutical innovation: the role of technological opportunities revisited," Journal of Evolutionary Economics, Springer, volume 27, issue 4, pages 691-727, September, DOI: 10.1007/s00191-017-0524-6.
• Frank R. Lichtenberg, 2017, "The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013," Latin American Economic Review, Springer;Centro de Investigaciòn y Docencia Económica (CIDE), volume 26, issue 1, pages 1-22, December, DOI: 10.1007/s40503-017-0045-6.
• Jannatul Ferdaous & Mohammad Mizanur Rahman, 2017, "The Effects of Research and Development Expenditure on Firm Performance: an Examination of Pharmaceuticals Industry in Bangladesh," Business & Entrepreneurship Journal, SCIENPRESS Ltd, volume 6, issue 2, pages 1-1.
• William Lazonick & Matt Hopkins & Ken Jacobson & Mustafa Erdem Sakinc & Oner Tulum, 2017, "US Pharma`s Financialized Business Model," Working Papers Series, Institute for New Economic Thinking, number 60, Jul, DOI: 10.2139/ssrn.3035529.
• Henry Grabowski & Carlos Brain & Anna Taub & Rahul Guha, 2017, "Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes," American Journal of Health Economics, MIT Press, volume 3, issue 1, pages 33-59, Winter.
• Henry Grabowski & Carlos Brain & Anna Taub & Rahul Guha, 2017, "Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes," American Journal of Health Economics, University of Chicago Press, volume 3, issue 1, pages 33-59, Winter.
• J.S Keshminder & VGR Chandran, 2017, "Eco-Innovation in the Chemical Manufacturing Firms: Insights for Policy Response," Institutions and Economies (formerly known as International Journal of Institutions and Economies), Faculty of Economics and Administration, University of Malaya, volume 9, issue 1, pages 21-42, January.
• Tsanko Valentinov Ivanov, 2017, "Methodological Framework for Analysis and Evaluation of Security Threats Within Industrial Enterprises," Business & Management Compass, University of Economics Varna, issue 3, pages 303-320.
• Diel, Anastasia & Kirchhoff, Jasmina, 2017, "Geringe Dynamik im Inlandsgeschäft: Deutschlands Pharmaindustrie 2016/2017," IW-Reports, Institut der deutschen Wirtschaft (IW) / German Economic Institute, number 36/2017.
• Kirchhoff, Jasmina, 2017, "Exportschlager Gesundheit: Wachstumstreiber Schwellenländer?," IW-Reports, Institut der deutschen Wirtschaft (IW) / German Economic Institute, number 6/2017.

2016

• Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016, "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, volume 106, issue 1, pages 136-164, January.
• Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2016, "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India," American Economic Review, American Economic Association, volume 106, issue 1, pages 99-135, January.
• Jonas Björnerstedt & Frank Verboven, 2016, "Does Merger Simulation Work? Evidence from the Swedish Analgesics Market," American Economic Journal: Applied Economics, American Economic Association, volume 8, issue 3, pages 125-164, July.
• Duncan S. Gilchrist, 2016, "Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals," American Economic Journal: Applied Economics, American Economic Association, volume 8, issue 4, pages 189-221, October.
• Rousselière, Samira & Rousselière, Damien & Ramani, Shyama, 2016, "Innovation Led Alliances: Theory and application to the GM Plant Industry," 2016 Annual Meeting, July 31-August 2, Boston, Massachusetts, Agricultural and Applied Economics Association, number 235711, DOI: 10.22004/ag.econ.235711.
• Rousselière, Samira & Rousselière, Damien & Ramani, Shyama, 2016, "Innovation Led Alliances: Theory and application to the GM Plant Industry," 149th Seminar, October 27-28, 2016, Rennes, France, European Association of Agricultural Economists, number 244949, DOI: 10.22004/ag.econ.244949.
• Richard A. Jensen, 2016, "University–Industry Linkages in the Support of Biotechnology Discoveries," Annual Review of Resource Economics, Annual Reviews, volume 8, issue 1, pages 377-396, October.
• Bojan Moric Milovanovic & Karla Kunst & Stjepan Srhoj, 2016, "Diagnosing Entrepreneurial Climate – Case Study In Pharmaceutical Industry," Economic Thought and Practice, Department of Economics and Business, University of Dubrovnik, volume 25, issue 1, pages 73-104, june.
• R. Cezar, 2016, "France’s pharmaceutical industry in global value chains," Quarterly selection of articles - Bulletin de la Banque de France, Banque de France, issue 44, pages 52-63, Winter.
• Simon P. Anderson & Federico Ciliberto & Jura Liaukonyte & Régis Renault, 2016, "Push-me pull-you: comparative advertising in the OTC analgesics industry," RAND Journal of Economics, RAND Corporation, volume 47, issue 4, pages 1029-1056, November.
• Granlund David & Köksal-Ayhan Miyase Yesim, 2016, "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals: Has the Price Competition increased?," The B.E. Journal of Economic Analysis & Policy, De Gruyter, volume 16, issue 2, pages 1069-1092, April, DOI: 10.1515/bejeap-2015-0127.
• Jens K. Perret, 2016, "Strukturwandel in der Europäischen Union am Beispiel ausgewählter Leitmärkte mit besonderem Bezug auf die Innovationstätigkeit der Mitgliedsländer," EIIW Discussion paper, Universitätsbibliothek Wuppertal, University Library, number disbei223, Oct.
• Villas-Boas, Sofia B & Carrera, Mariana, 2016, "Generic aversion and observational learning in the over-the-counter drug market," Department of Agricultural & Resource Economics, UC Berkeley, Working Paper Series, Department of Agricultural & Resource Economics, UC Berkeley, number qt0q03b5f2, Oct.
• José Morelos Gómez, 2016, "Análisis de la variación de la eficiencia en la producción de biocombustibles en América Latina," Estudios Gerenciales, Universidad Icesi, volume 32, issue 139, pages 120-126.
• Sylwester Bejger, 2016, "The specifics of supply chain of medical kits product group in the context of using Enterprise Resource Planning class systems," Ekonomia i Prawo, Uniwersytet Mikolaja Kopernika, volume 15, issue 4, pages 419-438, December, DOI: 10.12775/EiP.2016.028.
• Andreas Panagopoulos & Christos Pitelis & Panos Desyllas, 2016, "Cross-Border Co-opetition through Market Co-creation," Working Papers, University of Crete, Department of Economics, number 1612, Sep.
• LOPES, Joao Carlos & SANTOS, Ana, 2016, "Vertical Specialization, Global Value Chains And International Trade: The Rubber And Plastics Industry In Portugal And Comparison With Northern And Southern Eu Countries," Regional and Sectoral Economic Studies, Euro-American Association of Economic Development, volume 16, issue 2, pages 15-28.
• DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016, "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, volume 47, issue C, pages 20-33, DOI: 10.1016/j.jhealeco.2016.01.012.
• Krammer, Sorin M.S., 2016, "The role of diversification profiles and dyadic characteristics in the formation of technological alliances: Differences between exploitation and exploration in a low-tech industry," Research Policy, Elsevier, volume 45, issue 2, pages 517-532, DOI: 10.1016/j.respol.2015.10.014.
• Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2016, "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library, number 65415, Jan.
• Durgaprasad Navulla, 2016, "The Analysis of Industrial Sickness with Reference to the FCIL," GATR Journals, Global Academy of Training and Research (GATR) Enterprise, number jfbr115, Dec.
• Diego Useche & Philippe Gorry, 2016, "Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies," Post-Print, HAL, number hal-02195744, Jun.
• Luiz Flavio Andrade & Catherine Sermet & Sylvain Pichetti, 2016, "Entry time effects and follow-on drug competition," Post-Print, HAL, number halshs-01156509, DOI: 10.1007/s10198-014-0654-9.
• Bergman, Mats & Granlund, David & Rudholm, Niklas, 2016, "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," HUI Working Papers, HUI Research, number 116, Feb.
• Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016, "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies, Umeå University, Department of Economics, number 921, Feb.
• Fabio Pammolli & Armando Rungi, 2016, "Access to Medicines and European Market Integration," Working Papers, IMT School for Advanced Studies Lucca, number 01/2016, Jan, revised Jan 2016.
• Sergio Castro Aranda & Virginia Guadalupe Lopez Torres & Graciela Guerra Rivas, 2016, "Proposal Of Base Business Model For Biotechnology Companies In Mexico, Propuesta De Modelo De Negocio Base Para Las Empresas De Biotecnologia En Mexico," Revista Global de Negocios, The Institute for Business and Finance Research, volume 4, issue 4, pages 29-51.
• Quintana García, Cristina, 2016, "Impacto De La Mujer Directiva En La Salida A Bolsa De Empresas De Alta Tecnología: El Efecto Mediador De Las Patentes Y El Desarrollo De Productos / Impact Of Female Managers On High-Technology Firms Going Public: The Mediating Effect Of Patents And ," European Research on Management and Business Economics (ERMBE), Academia Europea de Dirección y Economía de la Empresa (AEDEM), volume 22, issue 2, pages 63-69.
• Florela Stoian, 2016, "The Growth Prospects for the World Tire Market in the Short and Medium-Term," Revista de Economie Mondiala / The Journal of Global Economics, Institute for World Economy, Romanian Academy, volume 8, issue 2.
• Andrew T. Ching & Robert Clark & Ignatius Horstmann & Hyunwoo Lim, 2016, "The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs," Marketing Science, INFORMS, volume 35, issue 1, pages 158-181, January, DOI: 10.1287/mksc.2015.0925.
• Sylvain Béal & Marc Deschamps, 2016, "On compensation schemes for data sharing within the European REACH legislation," European Journal of Law and Economics, Springer, volume 41, issue 1, pages 157-181, February, DOI: 10.1007/s10657-014-9468-6.
• Mats A. Bergman & David Granlund & Niklas Rudholm, 2016, "Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose," International Journal of Health Economics and Management, Springer, volume 16, issue 3, pages 201-214, September, DOI: 10.1007/s10754-016-9186-4.
• Dietrich Earnhart & Dylan G. Rassier, 2016, "“Effective regulatory stringency” and firms’ profitability: the effects of effluent limits and government monitoring," Journal of Regulatory Economics, Springer, volume 50, issue 2, pages 111-145, October, DOI: 10.1007/s11149-016-9304-8.
• Maria Letizia GIORGETTI & Maria Luisa MANCUSI, 2016, "Entry and Patenting in the Pharmaceutical Industry," Departmental Working Papers, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano, number 2016-02, Feb.
• Rena M. Conti & Ernst R. Berndt, 2016, "Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007," NBER Chapters, National Bureau of Economic Research, Inc, "Measuring and Modeling Health Care Costs".
• Mark Pauly & Kyle Myers, 2016, "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers, National Bureau of Economic Research, Inc, number 22720, Oct.
• Leemore Dafny & Christopher Ody & Matthew Schmitt, 2016, "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization," NBER Working Papers, National Bureau of Economic Research, Inc, number 22745, Oct.
• Ternus Lamb, Israel & Pacheco Lacerda, Daniel & Dresch, Aline, 2016, "A tecnologia empresarial Odebrecht como filosofia de projeto organizacional – um estudo de caso na Braskem S.A
  [Odebrecht entrepreneurial technology as organisational project philosophy – a case study in Braskem S.A]," MPRA Paper, University Library of Munich, Germany, number 82482, Aug, revised 20 May 2016.
• Doerhoefer, Steffen & Funder, Maria, 2016, "'You’ll (n)ever walk alone'. Innovative Wissensarbeit zwischen individualistischem Leistungsregime und kommunitaerer Teamkultur ('You’ll (n)ever walk alone'. Innovative knowledge work: Individual perf," Industrielle Beziehungen - Zeitschrift fuer Arbeit, Organisation und Management - The German Journal of Industrial Relations, Rainer Hampp Verlag, volume 23, issue 4, pages 458-476.
• Gloria Sheu & Andres Zahler & Eduardo Morales, 2016, "Extended Gravity," 2016 Meeting Papers, Society for Economic Dynamics, number 1565.
• Aas Mohammad & Bandi Kamaiah, 2016, "Efficiency Analysis of Indian Pharmaceutical Companies in the Post-TRIPS and Post Product Patent Regime using Stochastic Frontier Approach," Romanian Economic Journal, Department of International Business and Economics from the Academy of Economic Studies Bucharest, volume 19, issue 62, pages 5-24, December.
• Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016, "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," Proceedings of International Academic Conferences, International Institute of Social and Economic Sciences, number 4006562, Aug.
• Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016, "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," International Journal of Business and Management, International Institute of Social and Economic Sciences, volume 4, issue 3, pages 1-12, August.
• Luiz Andrade & Catherine Sermet & Sylvain Pichetti, 2016, "Entry time effects and follow-on drug competition," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 17, issue 1, pages 45-60, January, DOI: 10.1007/s10198-014-0654-9.
• Thomas Brenner & Johann Peter Murmann, 2016, "Using simulation experiments to test historical explanations: the development of the German dye industry 1857-1913," Journal of Evolutionary Economics, Springer, volume 26, issue 4, pages 907-932, October, DOI: 10.1007/s00191-015-0430-8.
• Mindaugas Kiškis & Tadas Limba & Gintarė Gulevičiūtė, 2016, "Business value of Intellectual Property in Biotech SMEs: case studies of Lithuanian and Arizona’s (US) firms," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, volume 4, issue 2, pages 221-234, December, DOI: 10.9770/jesi.2016.4.2(11).
• Dominik Heinisch & Önder Nomaler & Guido Buenstorf & Koen Frenken & Harry Lintsen, 2016, "Same place, same knowledge -- same people? The geography of non-patent citations in Dutch polymer patents," Economics of Innovation and New Technology, Taylor & Francis Journals, volume 25, issue 6, pages 553-572, September, DOI: 10.1080/10438599.2015.1081333.
• Tamires Ster de Paula Beltrão & Paulo Roberto Scalco, 2016, "O uso da inovação como estratégia competitiva no mercado de defensivos agrícolas no Brasil," REOESTE - Revista de Economia do Centro-Oeste, Nepec - Curso de Ciencias Economicas da Universidade Federal de Goias - FACE, volume 2, issue 1, pages 2-25.
• Hagedoorn, John & Lokshin, Boris & Malo, Stéphane, 2016, "Alliances and the innovation performance of corporate and public research spin-off firms," Research Memorandum, Maastricht University, Graduate School of Business and Economics (GSBE), number 041, Jan, DOI: 10.26481/umagsb.2016041.
• TUNSOIU, Nicolae & CITU, Daniela, 2016, "Logistic Flow Design For Sme`S," Journal of Financial and Monetary Economics, Centre of Financial and Monetary Research "Victor Slavescu", volume 3, issue 1, pages 165-171, October.
• Badi H. Baltagi & Peter H. Egger & Michaela Kesina, 2016, "Firm‐Level Productivity Spillovers in China's Chemical Industry: A Spatial Hausman‐Taylor Approach," Journal of Applied Econometrics, John Wiley & Sons, Ltd., volume 31, issue 1, pages 214-248, January.

2015

• Eric Budish & Benjamin N. Roin & Heidi Williams, 2015, "Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials," American Economic Review, American Economic Association, volume 105, issue 7, pages 2044-2085, July.
• David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015, "Pricing in the Market for Anticancer Drugs," Journal of Economic Perspectives, American Economic Association, volume 29, issue 1, pages 139-162, Winter.
• Tosun, Jale & Schaub, Simon, 2015, "To mobilize or not: political attention and the regulation of GMOs," GMCC-15: Seventh GMCC, November 17-20, 2015, Amsterdam, the Netherlands, International Conference on Coexistence between Genetically Modified (GM) and non-GM based Agricultural Supply Chains (GMCC), number 211493, Nov, DOI: 10.22004/ag.econ.211493.
• Vives-Vallés, J.A. & La Paz, J.L. & Corujo, M. & Martínez-Cañellas, A. & Galmés, J., 2015, "Field cross-fertilization between GM and non-GM maize in Mallorca: a Mediterranean insular approach," GMCC-15: Seventh GMCC, November 17-20, 2015, Amsterdam, the Netherlands, International Conference on Coexistence between Genetically Modified (GM) and non-GM based Agricultural Supply Chains (GMCC), number 211640, DOI: 10.22004/ag.econ.211640.
• Dmytro Gladkykh, 2015, "European Chemical Industry Competitiveness: Historical Trends And Development Prospects," Baltic Journal of Economic Studies, Publishing house "Baltija Publishing", volume 1, issue 1, DOI: 10.30525/2256-0742/2015-1-1-62-66.
• Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015, "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, volume 46, issue 4, pages 844-871, October.
• Granlund David, 2015, "The Effect of Pharmacies’ Right to Negotiate Discounts on the Market Share of Parallel Imported Pharmaceuticals," The B.E. Journal of Economic Analysis & Policy, De Gruyter, volume 15, issue 3, pages 1197-1235, July, DOI: 10.1515/bejeap-2014-0079.
• Andrew Ching & Robert Clark & Ignatius Horstmann & Hyunwoo Lim, 2015, "The Effects of Publicity on Demand: The Case of Anti-cholesterol Drugs," Working Papers, Canadian Centre for Health Economics, number 150007, Jun.
• Abud, María José & Hall, Bronwyn & Helmers, Christian, 2015, "An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile," Department of Economics, Working Paper Series, Department of Economics, Institute for Business and Economic Research, UC Berkeley, number qt9tv8s2rw, Jan.
• Frank Lichtenberg, 2015, "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series, CESifo, number 5166.
• Simon P. Anderson & Federico Ciliberto & Jura Liaukonyte & Régis Renault, 2015, "Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry," CESifo Working Paper Series, CESifo, number 5418.
• Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2015, "Price Regulation and Parallel Imports of Pharmaceuticals," CESifo Working Paper Series, CESifo, number 5469.
• Oscar Fabián García Aponte & Bibiana Margarita Vallejo D�az & Claudia Elizabeth Mora Huertas, 2015, "La calidad desde el diseno: principios y oportunidades para la industria farmacéutica," Estudios Gerenciales, Universidad Icesi.
• Gavazza, Alessandro & Galenianos, Manolis, 2015, "A Structural Model of the Retail Market for Illicit Drugs," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 10363, Jan.
• Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015, "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, volume 16, issue 2, pages 273-289, November.
• Sven Wydra & Timo Leimbach, 2015, "Integration von Industrie- und Innovationspolitik: Beispiele aus den USA und Israel und Ansätze der neuen EU-Industriepolitik," Vierteljahrshefte zur Wirtschaftsforschung / Quarterly Journal of Economic Research, DIW Berlin, German Institute for Economic Research, volume 84, issue 1, pages 121-134, DOI: 10.3790/vjh.84.1.121.
• Jiang, Jingze & Marsh, Thomas L. & Tozer, Peter R., 2015, "Policy induced price volatility transmission: Linking the U.S. crude oil, corn and plastics markets," Energy Economics, Elsevier, volume 52, issue PA, pages 217-227, DOI: 10.1016/j.eneco.2015.10.008.
• Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2015, "Location choice of academic entrepreneurs: Evidence from the US biotechnology industry," Journal of Business Venturing, Elsevier, volume 30, issue 2, pages 227-254, DOI: 10.1016/j.jbusvent.2014.02.002.
• Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015, "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, volume 129, issue C, pages 92-105, DOI: 10.1016/j.jpubeco.2015.08.002.
• Hostenkamp, Gisela & Lichtenberg, Frank R., 2015, "The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence," Social Science & Medicine, Elsevier, volume 130, issue C, pages 162-171, DOI: 10.1016/j.socscimed.2015.02.003.
• Skipper, Niels & Vejlin, Rune, 2015, "Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data," Social Science & Medicine, Elsevier, volume 130, issue C, pages 204-215, DOI: 10.1016/j.socscimed.2015.01.013.
• Dominik Heinisch & Önder Nomaler & Guido Buenstorf & Koen Frenken & Harry Lintsen, 2015, "Same Place, Same Knowledge – Same People? The Geography of Non-Patent Citations in Dutch Polymer Patents," Papers in Evolutionary Economic Geography (PEEG), Utrecht University, Department of Human Geography and Spatial Planning, Group Economic Geography, number 1526, Aug, revised Aug 2015.
• Stefan Dragutinovic, Jovan Zubovic, Marija Reljic, 2015, "Pharmaceutical Sector In Serbia In The Period 1990-2013," Ekonomika, Journal for Economic Theory and Practice and Social Issues, „Ekonomika“ Society of Economists, Niš (Serbia), number 2014-04, Jan.
• Jaime DE MELO, 2015, "Developing Countries in the World Economy," Working Papers, FERDI, number P128, May.
• Jaime DE MELO, 2015, "Developing Countries in the World Economy," Working Papers, FERDI, number P128, May.